Document is current
Any future updates will be listed below
-
Authors
Eloy, Catarina https://orcid.org/0000-0001-7642-1280
Fraggetta, Filippo
van Diest, Paul J.
Polónia, António
Curado, Mónica
Temprana-Salvador, Jordi
Zlobec, Inti
Purqueras, Elvira
Weis, Cleo-Aron
Matias-Guiu, Xavier
Schirmacher, Peter
Ryška, Aleš
-
Funding
Funding for this research was provided by:
Universidade do Porto
- License Information
-
More Information
Article History
Received: 22 January 2025
Revised: 18 March 2025
Accepted: 20 March 2025
First Online: 31 March 2025
Declarations
:
: Formal ethical approval was not required for this study, as it did not involve any patient data collection or impact on patient care.
: CE consulted for MSD, Biocartis, Diapath, Sakura and Diaceutics during the last 2 years. AP consulted for IndicaLabs for the last 2 years. AR declares participation at advisory board meetings by Amgen, AstraZeneca, Bayer, BMS, EliLilly, Gilead, Merck, MSD, Roche and Sanofi, invited speaker role at meetings organized by Amgen, BMS, EliLily, Gilead, Sanofi, Pfizer and Bayer, and travel support provided by Gilead and Sanofi. JT declares participation at advisory board meetings by MSD. PvD declares participation at advisory board meetings by Visiopharm, Sectra and Paige AI. XMG declares lectures and associated travel expenses: Roche Pharma, Qiagen, Ferrer Internacional, Novartis, Menarini, Biocartis, Agilent-Dako, Leica, Reig Jofre, Sysmex, MSD, AstraZeneca, BMS, GSK, Clovis; Advisory boards: AstraZeneca, Lilly, Amgen, GSK, Janssen, Illumina, MSD. IZ serves as scientific advisor for Aiforia. Other authors declare no conflicts of interests. The declared interests by the authors are not related to published content.
